T2	control 485 492	placebo
T4	outcome-Measure 649 679	12-month overall survival (OS)
T5	total-participants 916 919	939
T6	eligibility 65 147	nonanemic patients with metastatic breast cancer receiving first-line chemotherapy
T7	intervention-participants 957 960	469
T8	control-participants 975 978	470
T9	outcome 1101 1112	12-month OS
T10	iv-bin-percent 1117 1120	70%
T11	cv-bin-percent 1153 1156	76%
T3	outcome 1191 1213	Optimal tumor response
T12	outcome 1218 1245	time to disease progression
T13	intervention 42 54	epoetin alfa
